Best Medication for Anxiety
For an adult with generalized anxiety disorder and no contraindications, start with an SSRI—specifically escitalopram or sertraline—as your first-line pharmacologic treatment.
First-Line Treatment Approach
The evidence consistently supports selective serotonin reuptake inhibitors (SSRIs) as the safest and most effective initial pharmacotherapy for generalized anxiety disorder. Among SSRIs, escitalopram demonstrates superior efficacy in network meta-analyses, showing the greatest reduction in Hamilton Anxiety Scale scores (weighted mean difference -3.2) compared to other first-line agents 1. Sertraline is also recommended, particularly in older adults, due to its favorable side effect profile 2.
Why SSRIs First?
- Efficacy: 60-85% response rates across anxiety disorders 3
- Safety profile: Better tolerability than alternatives, with acceptability comparable to placebo in most trials 1
- No abuse potential: Unlike benzodiazepines
- Treats common comorbidities: Effective for co-occurring depression
Treatment Algorithm
Step 1: Initial SSRI Trial
Start with escitalopram (10-20 mg daily) or sertraline (50-200 mg daily). Allow 4-6 weeks for full therapeutic effect. If sexual side effects are a primary concern in a relatively healthy patient, consider buspirone (15-60 mg daily in divided doses) as an alternative first-line option 2.
Step 2: If Inadequate Response
Switch to a different SSRI or try an SNRI (serotonin-norepinephrine reuptake inhibitor):
- Duloxetine (60-120 mg daily) - shows excellent efficacy comparable to escitalopram 1
- Venlafaxine (75-225 mg daily) - well-established efficacy 4
Both duloxetine and venlafaxine are supported by robust evidence and are considered equivalent first-line options to SSRIs 5, 4, 6.
Step 3: Third-Line Options
If two adequate trials of SSRIs/SNRIs fail, consider:
- Pregabalin (150-600 mg daily) - most robust evidence among anticonvulsants 4, 7
- Gabapentin (900-3600 mg daily)
- Lavender oil (80-160 mg daily of silexan preparation) 2
Step 4: Augmentation Strategy
Quetiapine (50-300 mg daily) can be added as augmentation or monotherapy, though tolerability is lower than SSRIs/SNRIs 4, 7. Use the lowest effective dose to minimize metabolic side effects.
Critical Caveats
Benzodiazepines: Use With Extreme Caution
While benzodiazepines (lorazepam, alprazolam, clonazepam) are FDA-approved and rapidly effective, they should not be first-line due to:
- Dependence and withdrawal risks
- Cognitive impairment, especially in older adults
- Fall risk in elderly patients
- No treatment of underlying pathology
Reserve benzodiazepines for short-term use (2-4 weeks maximum) during SSRI/SNRI initiation if severe symptoms require immediate relief, then taper as the antidepressant takes effect 6, 2.
Medications Requiring Caution in Older Adults
In patients over 65, avoid or use cautiously 2:
- Benzodiazepines (increased fall risk, cognitive impairment)
- Hydroxyzine (anticholinergic effects)
- Higher doses of quetiapine (metabolic effects)
What About Combination Therapy?
Current guidelines provide no recommendation for routinely combining pharmacotherapy with psychotherapy initially, though cognitive behavioral therapy (CBT) is equally effective as monotherapy 5. In clinical practice, combining SSRI/SNRI with CBT may enhance outcomes, particularly in pediatric populations 6.
Monitoring and Duration
- Assess response at 4-6 weeks; full effect may take 8-12 weeks
- Continue effective treatment for at least 12 months after symptom remission to prevent relapse
- Taper slowly when discontinuing (over 4-8 weeks minimum) to avoid withdrawal symptoms
Special Populations
Pediatric patients: SSRIs remain first-line, with psychotherapy strongly recommended as adjunctive treatment to enhance response 6.
Older adults: Prefer sertraline or escitalopram; start at half the usual adult dose and titrate slowly 2.
Pregnant/breastfeeding: This population was excluded from the provided guidelines; consult specialized perinatal psychiatry resources.
The evidence base for GAD treatment is extensive, with SSRIs and SNRIs demonstrating the best balance of efficacy, safety, and tolerability for initial pharmacologic management 3, 4, 1, 6, 8.